Comparison of corticosteroid, autologous blood or sclerosant injections for chronic tennis elbow by Branson, R. et al.
Accepted Manuscript
Title: Comparison of corticosteroid, autologous blood or
sclerosant injections for chronic tennis elbow
Author: R. Branson K. Naidu C. du Toit A.H. Rotstein R.
Kiss D. McMillan L. Fooks B.K. Coombes B. Vicenzino
PII: S1440-2440(16)30226-2
DOI: http://dx.doi.org/doi:10.1016/j.jsams.2016.10.010
Reference: JSAMS 1412
To appear in: Journal of Science and Medicine in Sport
Received date: 6-3-2016
Revised date: 26-9-2016
Accepted date: 21-10-2016
Please cite this article as: BransonR,NaiduK, duToit C,RotsteinAH,KissR,McMillan
D, Fooks L, Coombes BK, Vicenzino B.Comparison of corticosteroid, autologous
blood or sclerosant injections for chronic tennis elbow.Journal of Science and Medicine
in Sport http://dx.doi.org/10.1016/j.jsams.2016.10.010
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Title: Comparison of corticosteroid, autologous blood or sclerosant injections for 
chronic tennis elbow. 
 
R Branson
a
, K Naidu
a
, C du Toit
a
, A.H Rotstein
b
, R Kiss
b
 D McMillan
a
, L Fooks
a
, B.K 
Coombes
c,d
, B Vicenzino
d 
 
a 
Olympic Park Sports Medicine Centre, AAMI Park, Olympic Boulevard, Melbourne, Vic, 
Australia 
b
 Victoria House Medical Imaging, MIA Radiology, 316 Malvern Road, Prahran, Vic, 
Australia 
c
 University of Queensland, School of Health and Rehabilitation Sciences, Physiotherapy, 
Queensland, Australia. 
d
 School of Biomedical Sciences, University of Queensland, Queensland, Australia 
 
Address for correspondence/reprints: 
Bill Vicenzino 
School of Health and Rehabilitation Sciences: Physiotherapy 
The University of Queensland, Building 84A, St Lucia QLD 4072 
Phone: + 617 3365 2781 Fax: + 617 3365 1622  Email: 
b.vicenzino@uq.edu.au 
  
Word count 2578 
1 Table, 2 Figures 
 
2 
 
Abstract 
Objectives: To compare three different ultrasound-guided injections for chronic tennis elbow  
Design: Assessor-blinded, randomized controlled comparative trial  
Methods: 44 patients with clinically diagnosed tennis elbow, confirmed by Doppler 
ultrasound, received under ultrasound guidance, a single corticosteroid injection (n=14), or 
two injections (separated by 4weeks) of either autologous blood (n=14) or polidocanol 
(n=16). Clinical and ultrasound examination was performed at baseline, 4,12 and 26weeks. 
Results: Complete recovery or much improvement was greater for corticosteroid injection 
than autologous blood and polidocanol at 4weeks (p<0.001, number needed to treat 1 (95% 
CI 1 to 2).  In contrast, at 26weeks corticosteroid was significantly worse than polidocanol 
(p=0.004, number needed to harm 2 (1 to 6).  Recurrence after corticosteroid injection was 
significantly higher than autologous blood or polidocanol (p=0.007, number needed to harm 2 
(1 to 4). Corticosteroid injection produced greater reduction in tendon thickness and 
vascularity than autologous blood at 4weeks only. Compared to autologous blood, 
polidocanol reduced tendon thickness at 4 and 12weeks and reduced echogenicity and 
hyperaemia after 12 or 26weeks respectively. 
Conclusions: Injections of corticosteroid cannot be recommended over polidocanol or 
autologous blood, because despite beneficial short-term effect there were inferior long-term 
effects. Whether polidocanol or autologous blood injections are effective is unknown, 
especially as their global effect profiles are not unlike previously reported for wait-and-see.  
Trial registration: ACTRN12614000398606 
Keywords 
Lateral epicondylalgia, polidocanol, blood products, ultrasonography, colour doppler 
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Introduction 
 
Tennis elbow affects approximately 1-3% of the general population
1-3
 and leads to 
considerable morbidity and economic burden.
4
 Corticosteroid injection has been in use since 
the 1950s and remains in widespread use,
5
 despite evidence it may be harmful over longer 
periods.
6, 7
 The last decade has seen the emergence of several novel injection therapies, 
including injection of the sclerosing agent, polidocanol
8, 9
 and autologous blood derived 
growth factors, either by whole blood or platelet rich plasma injections.
10-13
 There is little 
quality evidence to support of any of these injections over the others.
14, 15
  This is 
compounded by a lack of understanding of the complex pathophysiology of tennis elbow 
and/or the mechanisms of action of such injections, including their effect on tendon thickness, 
hyperaemia or echogenicity. Advances in colour/power-Doppler ultrasound have focused on 
detecting and quantifying the presence of neovessels and accompanying nerves,
16, 17
 with high 
diagnostic accuracy reported for tennis elbow.
16
 Despite this, few studies of tennis elbow have 
adopted diagnostic Doppler ultrasound as an eligibility criteria.  
 
We aimed to compare the effect of ultrasound-guided injections of corticosteroid, autologous 
blood and polidocanol on clinical outcomes, as well as musculoskeletal ultrasound 
examination findings in a population with unilateral tennis elbow with confirmed tendon 
neovascularity. 
 
Methods  
 
A randomized, assessor-blinded clinical trial was conducted within a community setting in 
Melbourne, Australia. Patients meeting a clinical diagnosis of tennis elbow and demonstrating 
neovascularisation on Doppler ultrasound were enrolled between January 2012 and 
September 2013.  Randomisation was by computer generated sequence. Concealed allocation 
was performed by drawing from opaque envelopes by a trial nurse not involved in the trial. 
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Ethical approval was obtained from the University of Queensland. Trial registration: 
ACTRN12614000398606. No financial support was received for this study. 
 
Patients with a provisional diagnosis of tennis elbow were referred to one of three private 
sports medicine clinics (Melbourne, Australia) from general practitioners, sport physicians 
and physiotherapists, or were self-referred after reading advertisements in the local paper. 
Potentially eligible patients underwent telephone and physical screening by one of the study 
sports physician registrars (R.B. or K.N.). Inclusion criteria were lateral elbow pain for more 
than 2 months, reproduced by resisted wrist and/or middle finger extension, tenderness over 
the lateral epicondyle and neovascularization on ultrasound examination.  Exclusion criteria 
were bilateral elbow pain or clinical symptoms suggestive of radioulnar joint synovitis or 
osteoarthritis, neurological symptoms or cervical radiculopathy. Patients who had received 
any injections into the common extensor tendon within the previous three months were 
excluded. 
 
Outcomes were assessed before randomisation, and at 4, 12 and 26weeks by assessors blinded 
to treatment. At each follow up, patients rated their Global Rating of Change (GROC) since 
baseline on a 6point Likert scale (completely recovered, much improved, improved, same, 
worse, much worse).  Consistent with previous studies,
6, 18, 19
 GROC scores were 
dichotomized (completely recovered or much improved versus improved, same, worse or 
much worse), while recurrence was defined as completely recovered or much improved at 
four weeks, but not at 12 or 26weeks.  
 
Secondary outcomes included measures of pain and disability, pain free grip strength and 
ultrasound characteristics. The Patient Rated Elbow Evaluation (PREE), now refined into the 
Patient Rated Tennis Elbow Evaluation (PRTEE),
20
 was used as a measure elbow pain and 
disability. It consisted of a series of questions on pain (5 items) and disability (15 items) 
experienced over the previous week rated on Likert scales. The total score out of 100 was 
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calculated by summing the pain items with the weighted disability score (15 items summed, 
divided by 3).  
 
Pain free grip strength was measured over both arms using digital dynamometry (MIE, 
Medical Research, Leeds, UK), according to published protocols,
21
 with established excellent 
reliability.
22
 The patient (positioned in supine and arm resting in pronation) was asked to grip 
until the first onset of pain or the first increase in pain (if resting pain was experienced). The 
mean of three efforts with rest periods of 30 seconds was computed and expressed as a ratio 
of affected to unaffected side.  
 
Ultrasound investigation was performed at Medical Imaging Australia (Melbourne, Australia) 
by a sonographer with 10years experience in musculoskeletal ultrasonography (R.K.) and 
reviewed by a musculoskeletal radiologist (A.R., P.S.). Ultrasound investigations were 
performed using GE Logiq E9 Ultrasound Machine (GE Healthcare UK) with Broadband 
Matrix Array Transducer (ML-6-15) operating at its highest frequency of 15MHz according 
to a standardised examination protocol.
16
 The patient was scanned while sitting with their arm 
relaxed on the table in 90° flexion.  
 
The common extensor tendon was first scanned in the longitudinal and transverse planes with 
B-Mode to record changes in overall echogenicity (classified on a four point scale as being 
normal, mild, moderate or severe) and the presence or absence of a tendon tear. Tendon 
thickness was measured in the longitudinal plane at the point of maximal tendon thickness at 
the epicondylar margin. This was followed by Colour Doppler imaging (pulse repetition 
frequency 10MHz, wall filter 75 Hz, colour gain of 86%). Care was taken to scan with light 
pressure in order to not compress the neovessels. The amount of colour doppler activity was 
quantified by the colour fraction, defined as the number of colour pixels divided by the total 
number of pixels in the region of interest.
17
 The region of interest was a standard sized ellipse 
(155.5mm2) placed over the common extensor origin in the longitudinal plane. A sweep of 
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the tendon was performed to identify the maximum colour fraction without flash artifact. 
Previous studies have found acceptable reliability for measurement of tendon thickness 
(ICC>0.76) and colour fraction measurement of vascularity (ICC=0.964)
23
 using similar 
techniques. 
 
Following baseline examination, an experienced musculoskeletal radiologist (A.R., P.S.) 
performed one of the following ultrasound guided injections using a 25g needle: (a) 
Corticosteroid: 1ml Betamethasone (Celestone Chondrose) was injected into the abnormal 
tendon and along the superficial tendon surface; (b) Autologous blood: Multiple dry needling 
punctures of the abnormal tendon were performed to cause local bleeding. A second 25g 
needle was then used to inject 3ml of autologous blood targeting the abnormal tendon area. 
(c) Polidocanol: 3ml Lauromacrogol was injected superficial to the tendon, targeting regions 
of neovascularity from lateral to medial back to the normal artery.  Prior to each injection, 3 
ml of blood was drawn from a cubital fossa vein of the other elbow in all patients, regardless 
of the allocated injection. Blood that was not used for injection was disposed in a safe 
manner. The patient was blindfolded so they could not see the syringe contents. The skin was 
prepared with a chlorhexidine wash and neovascularity sites were marked on the skin with a 
texta pen. No local anaesthetic was injected in any injection option.  
 
Following the injection all patients were seen by a physiotherapist who was unaware of the 
injection type. They were given an information sheet advising regarding general activity 
modification (e.g. avoidance of lifting objects with a pronated forearm), and taught an 
eccentric home exercise program. At the four week follow-up, patient reported outcomes and 
ultrasound examination were assessed by a radiographer who was not aware of the injection 
type. Following this, patients allocated to the autologous blood and polidocanol groups 
received a second ultrasound-guided injection. Patients were asked not to disclose the number 
of injections received to the physiotherapist or radiographer, who were both absent at the time 
of injection. 
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Analyses were performed using SPSS 20.0 on an intention-to-treat basis. Missing data for 
drop-outs were replaced with values carried forward. Binary outcomes were compared 
between groups using chi-squared statistics, with Bonferroni adjusted p-values. For 
continuous outcomes, change from baseline scores were computed and examined using 
analysis of variance, including time (within-subject) and treatment (between-subject) 
variables. Significant time by treatment interactions were present for all continuous outcomes 
(p<0.009), hence pairwise comparisons with Bonferroni correction are reported at each time 
point. P<0.05 was considered significant. 
 
The following point estimates of effect were computed for pairwise differences between 
treatments using RevMan 5.0.
24
 Relative risk (RR) was computed as the ratio of the risk of an 
event for two treatments. Standardized mean differences (SMD) expressed the size of the 
intervention effect relative to the variability. Effect sizes were considered large when absolute 
SMD was greater than 0.8 or RR was more than 2 or less than 0.5. Numbers needed to treat 
(NNT) or harm (NNH) were computed for primary outcomes to facilitate development of 
clinical guidelines for these treatments.  
 
Results  
Thirty-nine patients (88.6%) completed the trial.  Additional information about study 
eligibility is provided in supplemental material. Five patients (11%), each receiving 
corticosteroid, withdrew from the study after the 12week follow up, because of condition 
deterioration, hence were considered not successful for the primary outcome. Participants 
who withdrew were comparable on baseline demographic and clinical characteristics to 
participants who completed the trial. No other adverse events were reported.  
 
The groups were comparable at baseline on all demographic, clinical and ultrasound 
characteristics (Table 1). The study sample included 28 (64%) males, and had a mean (SD) 
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age of 48.0(7.5) years. The median (IQR) duration of symptoms was 5mths (4 -12) and mean 
(SD) PREE scores were 50.7 (16.5). Baseline ultrasound examination demonstrated 
moderate-severe changes in echogenicity and tendon tears in 27 (61%) and 15 (34%) patients 
respectively. Mean (SD) tendon thickness and colour fraction were 6.2(1.12)mm and 
0.17(0.11) respectively. Changes in clinical and ultrasound outcomes are presented in figure 1 
and table 2.  
Primary outcomes 
A significant effect of injection was found for ratings of complete recovery or much 
improvement at four weeks (p=0.002) and 26 weeks (p=0.01). Corticosteroid was superior to 
autologous blood and polidocanol at four weeks (RR >4.1, NNT 2). In contrast, after 26wks, 
corticosteroid was inferior to polidocanol (RR 0.4, NNH 2), while differences between 
corticosteroid and autologous blood neared significance (RR 0.4, p=0.058). No differences 
were seen between autologous blood or polidocanol at any time point.  
 
There was also a significant effect of injection on recurrence rate (p=0.001). Sixty-four 
percent of patients (9/14) treated with corticosteroid injection experienced recurrence, 
significantly higher than autologous blood (2/14, 14%) or polidocanol (1/16, 6%) (RR 0.4, 
NNH 2). There were no differences in recurrence between autologous blood and polidocanol.    
 
Secondary outcomes 
A significant effect of injection was found for changes in pain and disability (PREE, p=0.004) 
and pain free grip ratio (p=0.008) at four weeks only (Table 2, figure 1). Pairwise comparison 
indicated corticosteroid produced significantly greater improvement in pain and disability 
(SMD > 1.1) and pain free grip ratio (SMD > 1.1) compared to autologous blood or 
polidocanol. No differences were seen between autologous blood and polidocanol.  
 
A significant effect of injection was also found for changes in tendon thickness at 4 and 
12weeks (p=0.004, 0.038 respectively), hyperaemia at 4 and 26weeks (p<0.001, 0.028 
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respectively) and echogenicity at 12 weeks (p=0.003). Pairwise comparison revealed 
corticosteroid and polidocanol had significantly greater reduction in tendon thickness than 
autologous blood at four weeks (SMD >|0.8|). Improvement in tendon thickness remained 
higher for polidocanol than autologous blood at 12 weeks (SMD -1.0). Corticosteroid also 
showed greater reduction in hyperaemia than autologous blood or polidocanol (SMD >0.9) at 
4weeks. In contrast, polidocanol showed greater reduction in hyperaemia at 26 weeks than 
autologous blood (SMD -1.0). Polidocanol had a positive effect on echogenicity at 12weeks 
compared to corticosteroid or autologous blood (RR <0.5). There were no significant 
differences between treatments for ultrasound detection of tendon tears at any time point. 
 
Discussion  
This randomized controlled trial provides comparative efficacy and effect on ultrasound-
derived features of tendinopathy of three different injections for tennis elbow, each performed 
in a blinded manner under ultrasound guidance. Based on the primary outcome of complete 
recovery or much improvement, corticosteroid was superior to both autologous blood and 
polidocanol at four weeks, but worse at 26weeks than polidocanol. Recurrence was 
significantly higher after corticosteroid injection. The efficacy of autologous blood or 
polidocanol cannot be concluded from this trial. 
 
These data supports a previous meta-analysis,
7
 which concluded that corticosteroid injection 
is beneficial in the short term but detrimental in the long term and is associated with high 
recurrence rates, ranging from 64% in the current study to 55-72% in previous trials. 
Mirroring the pattern of recurrence observed using patient reported outcomes, corticosteroid 
had a large short-term effect on tendon thickness and hyperaemia compared to autologous 
blood but benefits were not maintained. In contrast, the pattern of global recovery for 
autologous blood and polidocanol injections appears very similar to that of placebo injection
6
 
or a wait and see approach
18
 demonstrated by previous studies of tennis elbow, and is in 
agreement with systematic reviews finding a lack of benefit on pain or overall recovery 
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following injections of polidocanol
7
 and autologous blood
25
 for tendinopathy. While 
autologous blood showed no improvement in tendon thickness or hyperaemia at any time 
point, polidocanol had a large effect on tendon thickness at 4 and 12weeks and produced 
superior improvements in echogenicity and hyperaemia after 12 and 26weeks respectively. 
Whether such response is linked to a clinically meaningful improvement remains to be 
determined. 
 
The strengths of this study include the blinded design, use of ultrasound to standardise the 
enrolled patients and the precise localization of the injection, 100% compliance and 0% drop-
outs except at six months. There are also limitations that need to be considered. A lack of 
placebo group is considered the greatest weakness, particularly given the efficacy of 
autologous blood and polidocanol is unclear, while that of corticosteroid injection is variable.  
The number of participants was relatively small and some of the near statistical significant 
effects are likely real, especially when considering that we elucidated substantial differences 
at both short and longer follow up on a range of outcomes. Success in blinding was not 
examined. Differing injection techniques and numbers of injections may have led to 
unblinding. For example, patients received a single corticosteroid injection or two injections 
of either autologous blood or polidocanol (at baseline and four weeks), based on study 
protocol. Given that 100% of corticosteroid injected patients reported complete recovery or 
much improvement at four weeks, a second injection may not be deemed clinically 
appropriate, although we cannot exclude that it may have improved late outcomes, given 
drop-outs were exclusive and high (36%) within this group. No local anaesthetic was used in 
the trial, although it is recognized that this does not reflect usual clinical practice. Patients 
also received instruction by a physiotherapist on eccentric home exercise, although 
monitoring of compliance to exercise or other co-interventions was not undertaken and may 
have influenced outcomes. A recent trial showed that addition of physiotherapy consisting of 
exercise and elbow mobilization to corticosteroid injection, did not change the characteristic 
response to corticosteroid injection.
6
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This study provides meaningful information about the numbers needed to treat or harm to 
facilitate informed treatment decisions about the comparative efficacy of common injections 
for tennis elbow. More research is needed to ascertain whether autologous blood or 
poliodocanol is (are) effective and whether subgroups of individuals may have a better 
response to one injection than another. Comprehensive ultrasound examination may be used 
to better understand the complex nature and temporal sequence of changes accompanying 
tendon pathology.
26
 
 
Conclusion 
Corticosteroid injection remains the best short-term option, but produces inferior patient 
reported outcomes compared to polidocanol and possibly autologous blood after 6 months. 
Superior long-term improvements in tendon thickness, hyperaemia and structure were seen 
following polidocanol, but it is of unclear significance. 
 
Practical implications 
 Corticosteroid injection is better than autologous blood or polidocanol in the short 
term but worse than polidocanol in the long term when considering overall recovery. 
 Corticosteroid injection produced only short-term benefit on tendon thickness and 
vascularity. 
 Polidocanol injection reduces tendon thickness, echogenicity and vascularity, 
although changes take at least 12 weeks, but this is of unclear significance. 
 While we did not use a placebo comparator, the use of polidocanol or autologous 
blood is questionable, given that their outcome trajectories parallel that of wait-and-
see approach in previous trials.  
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Tables 
 
 
Table 1 Baseline demographic, clinical and ultrasound measures for patients treated 
by corticosteroid injection (CSI), autologous blood injection (ABI) and polidocanol 
injection (POL). 
  
CSI  
n=14 
ABI  
n=14 
POL  
n=16 
Total population 
n=44 
Demographic characteristics 
Age (years) 48.1 (8.1) 47.9 (6.9) 47.9 (7.8) 48.0 (7.5) 
Male n (%) 8 (57%) 10 (71%) 10 (63%) 28 (64%) 
Clinical measures     
Duration (median IQR) (months) 4.5 (3.0, 7.5) 5.5 (3.0, 12.5) 5.0 (4.0, 12.0) 5 (4,12) 
Pain and disability  
(PREE, 0-100) 48.5 (17.2) 52.0 (13.8) 51.0  (17.6) 50.7 (16.5) 
PFG ratio (Affected/unaffected) 0.39 (0.21) 0.42 (0.26) 0.58 (0.32) 0.47 (0.28) 
Ultrasound measures     
Tendon thickness (mm) 6.38 (1.16) 6.07 (0.90) 6.14 (1.29) 6.20 (1.12) 
Hyperaemia colour fraction (0-1) 0.2 (0.11) 0.14 (0.09) 0.16 (0.11) 0.17 (0.11) 
Tears (%) 6 (43%) 4 (29%) 5 (31%) 15 (34%) 
Moderate-severe echogenicity 
(%) 10 (71%) 9 (64%) 8 (50%) 27 (61%) 
Data represents mean (SD) or frequency (%), unless otherwise specified. No 
significant differences were observed between groups at baseline. Abbreviations: 
PREE Patient rated elbow evaluation; PFG pain free grip  
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Table 2 Effect of corticosteroid injection (CSI), autologous blood injection (ABI) and 
polidocanol injection (POL) on primary and secondary outcomes. 
     
Between-group comparisons 
(SMD or RR, 95% CI) 
  CSI n=14 ABI n=14 POL n=16   CSI v ABI CSI v POL ABI v POL 
Primary outcome measures 
Complete recovery or much improvement  
4wks 
 
14 (100%) 
 
3 (21%) 
 
2 (13%) 
 
RR 
NNT 
4.1 (1.7, 10.4)*  
2 (1,1.8)* 
6.6 (2.1, 20.7)* 
2 (1,1.4)* 
1.7 (0.3, 8.8) 
12 (2.8,-5.6) 
12wks 
 
6 (43%) 
 
5 (36%) 
 
6 (38%) 
 
RR 
NNT 
1.2 (0.5,3.0) 
14 (2.3,-3.5) 
1.1 (0.5,2.7) 
19 (2.5,-3.4) 
1.0 (0.4, 2.5) 
NNH 56 (-2.8,3.1) 
26wks 
 
4 (29%) 
 
9 (64%) 
 
13 (81%) 
 
RR 
NNH 
0.4 (0.2, 1.1) 
3 (1.4,82.1) 
0.4 (0.2, 0.8)* 
2 (1.2,4.5)* 
0.8 (0.5, 1.3) 
6 (-2.1,6.9) 
Recurrence § 
 
9 (64%) 
 
2 (14%) 
 
1 (6%) 
 
RR 
NNH 
0.4 (0.2, 0.9)* 
2 (1.2,5.3)* 
0.4 (0.2, 0.8)* 
2 (1.2,3.3)* 
0.9 (0.7, 1.2) 
13 (-3.3,7.2) 
Secondary clinical outcome measures  
Improvement in pain and disability (PREE, 0-100)  
4wks 36.0 (19.6) 13.6 (21.5) 9.2 (20.7) SMD 1.1 (0.2,1.9)* 1.3 (0.5,2.1)* 0.2 (-0.4,0.8) 
12wks 17.9 (22.5) 17.8 (18.3) 19.9 (22.7) SMD  0.0 (-0.8,0.8) -0.1 (-0.8,0.7) -0.1 (-0.9,0.7) 
26wks 19.2 (23.1) 29.4 (22.5) 28.9 (21.2) SMD -0.4 (-1.3,0.4) -0.4 (-1.2,0.3) 0.1 (-0.3,0.5) 
Improvement in pain free grip ratio (affected/unaffected)  
4wks 0.49 (0.22) 0.16 (0.37) 0.17 (0.29) SMD 1.1 (0.3, 1.9)* 1.2 (0.4, 2.0)* -0.03(-0.8, 0.7) 
12wks 0.29 (0.29) 0.40 (0.28) 0.20 (0.34) SMD -0.4 (-1.1, 0.4) 0.3 (-0.5, 1.0) 0.6 (-0.1, 1.4) 
26wks 0.25 (0.34) 0.46 (0.20) 0.33 (0.35) SMD -0.7 (-1.5, 0.04) -0.2 (-1.0, 0.5) 0.4 (-0.3, 1.2) 
Secondary ultrasound outcome measure 
Reduction in tendon thickness (mm)  
4wks 0.58 (0.66) -0.21 (0.45) 0.23 (0.61) SMD 1.4 (0.5, 2.1)* 0.6 (-0.2, 1.3) -0.8(-1.5, -0.04)* 
12wks 0.06 (0.61) -0.16 (0.35) 0.36 (0.60) SMD 0.3 (-0.4, 1.1) -0.6 (-1.3, 0.2) -1.0 (-1.8, -0.2)* 
26wks 0.25 (0.55) -0.20 (0.58) 0.27 (0.65) SMD 0.7 (-0.04, 1.5) -0.03 (-0.8, 0.7) -0.8 (-1.5, -0.02) 
Reduction in hyperaemia (colour fraction)  
4wks 0.13 (0.13) -0.03 (0.07) 0.03 (0.07) SMD 1.5 (0.6, 2.3)* 0.9 (0.1, 1.7)* -0.8 (-1.5,0.01) 
12wks -0.01 (0.10) -0.03 (0.06) 0.01 (0.08) SMD 0.2 (-0.5. 1.0) -0.2 (-1.0, 0.5) -0.6 (-1.3, 0.2) 
26wks -0.01 (0.09) -0.04 (0.09) 0.05 (0.09) SMD -0.3 (-0.4, 1.4) -0.7 (-1.5, 0.02) -1.0 (-1.8,-0.2)* 
Echogenicity (moderate-severe) (%) 
4wks 5/14 (36%) 9/14 (64%) 6/16 (38%) RR 1.8 (0.8, 4.0) 1.0 (0.6, 1.8) 0.6 (0.3, 1.3) 
12wks 10/14 (71%) 8/14 (57%) 2/16 (13%) RR 0.7 (0.2, 1.9) 0.3 (0.1, 0.8)* 0.5 (0.3, 0.9)* 
26wks 8/14 (57%) 6/14 (43%) 4/16 (25%) RR 0.8 (0.4, 1.6) 0.6 (0.3, 1.1) 0.8 (0.5, 1.3) 
Tears (%) 
4wks 8/14 (57%) 3/14 (21%) 7/16 (44%) RR 0.6 (0.3, 1.1) 0.8 (0.4, 1.6) 1.4 (0.8, 2.3) 
12wks 5/14 (36%) 3/14 (21%) 4/16 (25%) RR 0.8 (0.5, 1.3) 0.9 (0.5, 1.4) 1.1 (0.7, 1.6) 
26wks 4/14 (29%) 1/14 (7%) 3/16 (19%) RR 0.8 (0.5, 1.1) 0.9 (0.6, 1.3) 1.1 (0.9, 1.5) 
Summary data are represented by no. events/total sample at each time point (%) or mean 
change from baseline (SD), unless otherwise specified. Pairwise differences between 
treatments for categorical or continuous outcomes are represented by relative risk (RR) or 
standardized mean differences (SMD) respectively. RR>1 and SMD>0 represent differences 
18 
 
in favour of the first listed injection. NNT number needed to treat; NNH number needed to 
harm. Significant pairwise differences between treatments, as determined by Pearson chi-
squared or univariate analysis of variance (p<0.05) are indicated by an asterisk. § Recurrence 
is defined as complete recovery or much improvement at four weeks, but not at either 12 or 
26weeks. PREE Patient rated elbow evaluation. 
 
  
19 
 
Figure 1: Proportion of patients reporting complete recovery or much improvement at each 
timepoint. Mean (SE) change from baseline for continuous outcomes for the three treatments.  
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Time point (weeks) 
4                12                              26 
